PSPadmini Selvaganesan

Padmini Selvaganesan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Padmini Selvaganesan has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Glucagon‐Like Peptide‐1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction

    by Padmini Selvaganesan, Mohamad Karnib, Irfan Helmy, Rosita Zakeri, Yusef Babar Saeed, Jayakumar Sahadevan, Mohammed Najeeb Osman, Anirban Mondal, Sherry Milfred‐LaForest, James C. Fang, et al.

    Background: To evaluate whether GLP‐1 (glucagon‐like peptide‐1) receptor agonists (GLP‐1RAs), compared with DPP4 (dipeptidyl peptidase‐4) inhibitors or sulfonylureas, are associated with reduced all‐cause mortality or heart failure hospitalizations in patients with obesity and type 2 diabetes, and heart failure with preserved ejection fraction. Methods: PRAISE‐HFpEF (Glucagon‐Like Peptide‐1 Receptor Agonist in Obese Heart Failure With Preserved Ejection Fraction) was a nationwide multicenter cohort study using a new‐user, active‐comparator design within the national Veterans Affairs Health System (170 US hospitals). Adults with type 2 diabetes between January 1, 2000 and December 31, 2021, were identified from centralized electronic health records. Patients with heart failure with preserved ejection fraction and a body mass index ≥30 kg/m 2 were selected using a validated diagnostic algorithm. Exposure was initiation of a GLP‐1RA versus DPP4 inhibitors/sulfonylurea from January 1, 2015 to December 31, 2021. The primary outcome was time to all‐cause mortality or heart failure hospitalization. Inverse probability of treatment weighting based on the propensity score was used to balanced baseline characteristics. Results: Among 179 288 patients with type 2 diabetes, obesity, and heart failure with preserved ejection fraction, 1024 GLP‐1RA users and 796 DPP4 inhibitors/sulfonylurea users met inclusion criteria. Over a median follow‐up of 1.5 years, GLP‐1RA use was associated with a lower risk of the primary outcome (adjusted hazard ratio, 0.78 [95% CI, 0.64–0.95], P =0.01). Weight loss was modestly greater with GLP‐1RAs compared with DPP4 inhibitors/sulfonylurea (−12.9% versus −10.1%). Conclusions: Among patients with obese heart failure with preserved ejection fraction and type 2 diabetes, GLP‐1RA initiation was associated with a lower incidence of death or heart failure hospitalization compared with alternative oral agents.

  • Antecedent Kidney Function and Cardiovascular Mortality in Over 300 000 Patients With Incident Heart Failure With Preserved Ejection Fraction

    by Mohamad Karnib, Padmini Selvaganesan, Irfan Helmy, Rosita Zakeri, Yusef Babar Saeed, Mohammed Najeeb Osman, Jayakumar Sahadevan, Amanda Ruth Vest, Yogesh N.V. Reddy, Varun Sundaram

    BACKGROUND: Chronic kidney disease is a frequent comorbidity in heart failure with preserved ejection fraction (HFpEF) and has been proposed as a contributor to its development. However, the spectrum of antecedent kidney function before incident HFpEF and its association with subsequent cardiovascular outcomes remains unclear. METHODS: We conducted a multicenter cohort study across 170 US Veterans Affairs hospitals, including patients with incident HFpEF diagnosed between January 1, 2000, and June 30, 2025. HFpEF was ascertained using natural language processing-derived left ventricular ejection fraction ≥50% closest to the incident HF date and a validated HFpEF algorithm incorporating loop diuretic use, elevated natriuretic peptide levels, and an HFpEF–age, body mass index, and atrial fibrillation score >0.5. Antecedent kidney function was classified using 2 estimated glomerular filtration rate (eGFR) measurements obtained ≥90 days apart before incident HFpEF and urine albumin-to-creatinine ratio. We characterized antecedent kidney function, including albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g), and examined its associations with 5-year cardiovascular death and heart failure hospitalization. Competing-risk analysis was performed accounting for noncardiovascular death as a competing event for cardiovascular death. RESULTS: Of 304 712 patients meeting HFpEF ascertainment criteria, 236 910 comprised the final cohort; 51% had antecedent eGFR ≥60 mL/min per 1.73m 2 . Overall, 15% had an eGFR ≥90 mL/min per 1.73m 2 . Patients with eGFR 2 were older and had more diabetes and hypertension. 51% of the patients with eGFR 2 had body mass index 2 , including 20% with body mass index 2 . Progressively lower antecedent kidney function was associated with graded increases in cardiovascular death and heart failure hospitalization. Among decedents, the proportion of deaths attributed to cardiovascular causes increased from 25% in the preserved eGFR (≥90 mL/min per 1.73m 2 ) without documented albuminuria to 32% with albuminuria and 38% with advanced kidney dysfunction ( P <0.001). CONCLUSIONS: In this nationwide study of patients with incident HFpEF, antecedent kidney dysfunction was common but not uniformly present before HFpEF onset. Furthermore, among patients who developed HFpEF, antecedent kidney dysfunction identified a higher-risk phenotype, with progressively greater cardiovascular mortality and heart failure hospitalization with declining kidney function.

  • Cardiac Resynchronization With or Without Defibrillator in Nonischemic Cardiomyopathy: A Nationwide Cohort Study (DECIDE-CRT)

    by Padmini Selvaganesan, Mohamad Karnib, Irfan Helmy, Yogesh N.V. Reddy, Imran Rashid, Mohammed N. Osman, Ram Amuthan, Amanda R. Vest, Anselma Intini, James C. Fang, et al.

    BACKGROUND: With evolving therapy for heart failure with reduced ejection fraction, the benefits of adding a defibrillator in patients undergoing cardiac resynchronization therapy (CRT) remain unclear, particularly for nonischemic cardiomyopathy (NICM). This study evaluates long-term survival among patients with NICM treated with CRT defibrillator (CRT-D) versus CRT pacemaker (CRT-P). METHODS: DECIDE-CRT (Cardiac Resynchronization With or Without Defibrillator in Non-Ischemic Cardiomyopathy) is a multicenter cohort study across 170 US Veterans Affairs hospitals. We identified patients with NICM receiving primary-prevention CRT-P or CRT-D between January 1, 2006, and December 31, 2020. Using a propensity score approach, we applied inverse probability of treatment weighting to balance baseline characteristics between the CRT-P and CRT-D groups. An inverse probability of treatment weighting–weighted Cox model estimated hazards for all-cause mortality. Secondary outcomes included generator replacement, device-related infections, hospitalization for heart failure, and ventricular arrhythmias. RESULTS: Of 16 609 CRT recipients, 3965 met NICM primary-prevention criteria (CRT-D=3158; CRT- P =807). At baseline, patients with NICM receiving CRT-P were much older, with more cardiovascular and noncardiovascular comorbidities compared with the CRT-D group. During the median follow-up of 5.2 years, the mortality rate for CRT-P versus CRT-D was 9.46 versus 9.21 per 100 person-years (rate ratio, 0.97 [95% CI, 0.71–1.13]; P =0.66). The adjusted hazard ratio for all-cause mortality using the inverse probability of treatment weighting-Cox model was 0.90 (95% CI, 0.71–1.13; P =0.34). There was no difference in adjusted hazard for heart failure hospitalization (hazard ratio, 1.27 [95% CI, 0.86–1.87]), while the CRT-D group had higher rates of generator replacement and device-related infections. CONCLUSIONS: This nationwide observational study from the Veterans Affairs Health system did not demonstrate a clear survival advantage with the addition of a defibrillator among patients with NICM receiving CRT although residual confounding cannot be excluded. Given the uncertainty surrounding the incremental benefit of the defibrillator in this setting, a randomized trial is needed to test the incremental value of CRT-D over CRT-P in NICM.

  • Pre-operative glycaemic control and long-term survival in diabetic patients after coronary artery bypass grafting

    by Salil Deo, Varun Sundaram, Muhammad Adil Sheikh, Jayakumar Sahadevan, Padmini Selvaganesan, Sri Krishna Madan Mohan, Joseph Rubelowsky, Yakov Elgudin, Richard Josephson, Piroze M Davierwala, et al.

    : OBJECTIVES: We analysed the Veteran Affairs data to evaluate the association of pre-operative glycated haemoglobin (HbA1c) and long-term outcome after isolated coronary artery bypass grafting (CABG). METHODS: Veterans with diabetes mellitus and isolated CABG (2006–2018) were divided into 4 groups (I: HbA1c 10%). The relationship of pre-operative HbA1c and long-term survival was evaluated with a multivariable Cox proportional hazards model and reported as hazard ratios (HR). The cumulative incidence of secondary end-points [myocardial infarction (MI) and repeat revascularization (percutaneous intervention)] for each group was modelled as competing events with cause-specific Cox proportional hazards models. RESULTS: Overall, 16 190 patients (mean age 64.9 years, male 98%; insulin dependent 53%) with diabetes mellitus underwent isolated CABG. We observed 19.4%, 45.4%, 27% and 8.2% patients in groups I, II, III and IV, respectively. Patients with HbA1c >10% were the youngest (mean age 60.9 years) and had high rates of Insulin dependence (78%). In patients with HbA1c >10%, improvement in levels was observed in 76%. The median follow-up observed was 5.8 (3.2–8.8) years. Compared to the study mean HbA1c (7.3%), mortality rate increased with HbA1c levels >8%, and especially with pre-operative HbA1c levels >9%. Compared to patients with HbA1c 10% were associated with increased MI (HR 1.24 and HR 1.39, respectively) and need for reintervention (HR 1.20 and HR 1.24, respectively). CONCLUSIONS: In patients undergoing CABG, pre-operative HbA1c >8% is associated with the increased risk of mortality and adverse cardiac events.


  • CHA2DS2-VASC SCORE RATHER THAN NEW-ONSET ATRIAL FIBRILLATION INFLUENCES STROKE RISK AFTER ISOLATED CORONARY ARTERY BYPASS GRAFTING - A NATIONWIDE STUDY

    by Salil Deo, Varun Sundaram, Padmini Selvaganesan, Joseph Rubelowsky, Yakov Elgudin, Sri Krishna Madan Mohan, Richard Josephson, Salah Altarabsheh, Brian Cmolik, Piroze Davierwala, et al.

  • A NATIONWIDE ANALYSIS OF THE EXTERNAL APPLICABILITY OF THE COMPASS TRIAL IN PATIENTS UNDERGOING CORONARY ARTERY BYPASS SURGERY

    by Salil Deo, Jayakumar Sahadevan, Muhammad Adil Sheikh, Padmini Selvaganesan, Shrikrishna Madan Mohan, Richard Josephson, Joseph Rubelowsky, Yakov Elgudin, Brian Cmolik, Salah Altarabsheh, et al.

  • CORONARY ARTERY BYPASS GRAFTING IMPROVES 10 YEAR OUTCOMES IN HEART FAILURE AND PRESERVED EJECTION FRACTION - A NATIONWIDE STUDY

    by Salil Deo, Yogesh Reddy, Padmini Selvaganesan, Joseph Rubelowsky, Yakov Elgudin, Sri Krishna Madan Mohan, Richard Josephson, Brian Cmolik, Ahmet Kilic, Jayakumar Sahadevan, et al.